CervoMed neflamapimod Phase 2a nfvPPA biomarker data set for ISFTD 2026 oral session

PUBT · 2d ago
CervoMed neflamapimod Phase 2a nfvPPA biomarker data set for ISFTD 2026 oral session
  • CervoMed set an ISFTD 2026 late-breaking oral session to disclose initial biomarker results from its Phase 2a neflamapimod trial in nfvPPA.
  • Data will be presented Oct. 11, 2026, shifting from an earlier abstract based on the first eight participants to results from at least 22.
  • The initial readout points to measurable biological effects over 12 weeks, supporting continued evaluation in a disease with no approved therapies.
  • Enrollment is complete at 25 participants across U.S. and U.K. academic centers, with the study assessing safety, drug exposure, and clinical effects.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609100730PRIMZONEFULLFEED9824175) on September 10, 2026, and is solely responsible for the information contained therein.